Recorded Presentations from the NCCN 2024 Pharmacy Updates: A Webinar Series

The rapid integration of new therapeutic agents into treatment for various types of cancer can be challenging for clinicians. Cancer treatment is constantly evolving, and it is crucial for health care professionals to stay up to date with the latest developments in the field. Pharmacists are critical to educating the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options. Pharmacists also have an important role in patient safety, education, and quality of care, as well as subsequent monitoring and management of treatment-related toxicities.

This program will provide up-to-date knowledge and skills related to the management of cancer and highlight the importance of interprofessional care and collaboration to ensure the best possible outcomes for patients with cancer.

Target Audience

This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants and other health care professionals who manage patients with cancer.

Learning Objectives

The goal of this project is to ensure that pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants, and other members of the interprofessional oncology care team who manage patients with cancer have the knowledge and skills necessary to:

Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
Communicate the importance of an interprofessional approach and improve the collaborative performance of the oncology care team in the management of patients with cancer.

Additional information

Supporters:

This activity is supported by educational grants from GSK and Menarini-Stemline. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Course summary

Course opens:

03/18/2024

Course expires:

12/31/2025

Cost:

$0.00

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Full disclosure of faculty relationships will be made prior to the activity.

This educational program is approved for continuing education credit for pharmacists, physicians, nurses, PAs, and other oncology professionals. Complete accreditation information is provided before each individual educational activity.

Status

Price

Title

Locked

$0.00Included

Recorded Presentations from the NCCN 2024 Pharmacy Updates: A Webinar Series